High Expression Level of EDIL3 in HCC Predicts Poor Prognosis of HCC Patients

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2010 Sep 22

PMID 20857535

Citations 22

Authors

Jian-Cong Sun

Xiao-Ting Liang

Ke Pan

Hui Wang

Jing-Jing Zhao

Jian-Jun Li

Hai-Qing Ma

Yi-Bing Chen

Jian-Chuan Xia

Affiliations

Soon will be listed here.

Abstract

Aim: To determine the role of epidermal growth factor-like repeats and discoidin I-like domains 3 (EDIL3) in pathogenesis of hepatocellular carcinoma (HCC) by investigating the EDIL3 expression in HCC and its prognostic value for HCC.

Methods: EDIL3 expression was detected in 101 HCC surgical tissue samples with immunohistochemistry method, and its relation with clinicopathologic features and prognosis of HCC patients was analyzed.

Results: EDIL3 was highly expressed in 48.5% of the HCC patients. Although the EDIL3 expression level did not correlate with any clinicopathological parameters, Kaplan-Meier survival analysis showed that high expression level of EDIL3 resulted in a significantly poor prognosis of HCC patients (log-rank test, P = 0.010). Multivariate Cox's analysis showed that the EDIL3 expression level was a significant and independent prognostic parameter for the overall survival rate of HCC patients (hazard ratio = 1.978, 95% confidence interval = 1.139-3.435, P = 0.015).

Conclusion: High expression level of EDIL3 predicts poor prognosis of HCC patients. EDIL3 may be a potential target of antiangiogenic therapy for HCC.

Citing Articles

Oncogenic and immunological role of EDIL3 in human tumours: From pan-cancer analysis to validation in gastric cancer.

Ke B, Jin P, Wang X, Liu N, Liang H, Zhang R Heliyon. 2024; 10(11):e32291.

PMID: 38882287 PMC: 11180325. DOI: 10.1016/j.heliyon.2024.e32291.

Dysregulation of the Skin-Liver Axis in Prurigo Nodularis: An Integrated Genomic, Transcriptomic, and Population-Based Analysis.

Marani M, Madan V, Le T, Deng J, Lee K, Ma E Genes (Basel). 2024; 15(2).

PMID: 38397136 PMC: 10887737. DOI: 10.3390/genes15020146.

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade.

Tabasum S, Thapa D, Giobbie-Hurder A, Weirather J, Campisi M, Schol P Cancer Immunol Res. 2023; 11(11):1493-1507.

PMID: 37728484 PMC: 10618652. DOI: 10.1158/2326-6066.CIR-23-0171.

EDIL3 is a potential prognostic biomarker that correlates with immune infiltrates in gastric cancer.

Ke B, Liang Z, Li B, Wang X, Liu N, Liang H PeerJ. 2023; 11:e15559.

PMID: 37576496 PMC: 10422953. DOI: 10.7717/peerj.15559.

EDIL3 regulates gastric cancer cell migration, invasion and epithelial-mesenchymal transition via TGF-β1/XIST/miR-137 feedback loop.

Zhang L, Peng K, Wang B, Yang X, Zhang Z Transl Cancer Res. 2022; 9(10):6313-6330.

PMID: 35117240 PMC: 8799203. DOI: 10.21037/tcr-19-2967b.

References

Rajagopalan S, Olin J, Young S, Erikson M, Grossman P, Mendelsohn F . Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther. 2004; 15(6):619-24. DOI: 10.1089/104303404323142060. View

Poon D, Anderson B, Chen L, Tanaka K, Lau W, Van Cutsem E . Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10(11):1111-8. DOI: 10.1016/S1470-2045(09)70241-4. View

Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T . Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998; 27(6):1554-62. DOI: 10.1002/hep.510270613. View

Aoka Y, Johnson F, Penta K, Hidai C, Schatzman R, Varner J . The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. Microvasc Res. 2002; 64(1):148-61. DOI: 10.1006/mvre.2002.2414. View

Hidai C, Kawana M, Habu K, Kazama H, Kawase Y, Iwata T . Overexpression of the Del1 gene causes dendritic branching in the mouse mesentery. Anat Rec A Discov Mol Cell Evol Biol. 2005; 287(2):1165-75. DOI: 10.1002/ar.a.20247. View

Grossman P, Mendelsohn F, Henry T, Hermiller J, Litt M, Saucedo J . Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J. 2007; 153(5):874-80. DOI: 10.1016/j.ahj.2007.01.038. View

Pang R, Poon R . Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006; 242(2):151-67. DOI: 10.1016/j.canlet.2006.01.008. View

Niu J, Zhang W, Ye L, Wu L, Zhu G, Yang Z . The role of adhesion molecules, alpha v beta 3, alpha v beta 5 and their ligands in the tumor cell and endothelial cell adhesion. Eur J Cancer Prev. 2007; 16(6):517-27. DOI: 10.1097/CEJ.0b013e3280145c00. View

Hidai C, Zupancic T, Penta K, Mikhail A, Kawana M, Quertermous E . Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes Dev. 1998; 12(1):21-33. PMC: 529342. DOI: 10.1101/gad.12.1.21. View

10.

Fan Y, Zhu W, Yang M, Zhu Y, Shen F, Hao Q . Del-1 gene transfer induces cerebral angiogenesis in mice. Brain Res. 2008; 1219:1-7. PMC: 2553757. DOI: 10.1016/j.brainres.2008.05.003. View

11.

Quezada A, Larson J, French M, Ponce R, Perrard J, Durland R . Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. J Pharm Pharmacol. 2004; 56(2):177-85. DOI: 10.1211/0022357022584. View

12.

Yamamoto A, Dhar D, Igarashi M, Tabara H, Nagasue N . Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol. 1998; 29(2):290-9. DOI: 10.1016/s0168-8278(98)80015-9. View

13.

Poon R, Ng I, Lau C, Yu W, Yang Z, Fan S . Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol. 2002; 20(7):1775-85. DOI: 10.1200/JCO.2002.07.089. View

14.

Zou X, Qiao H, Jiang X, Dong X, Jiang H, Sun X . Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. J Biomed Sci. 2009; 16:33. PMC: 2666667. DOI: 10.1186/1423-0127-16-33. View

15.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

16.

Sun H, Tang Z, Li X, Zhou Y, Sun B, Ma Z . Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol. 1999; 125(7):419-26. DOI: 10.1007/s004320050296. View

17.

Luo J, Ren B, Keryanov S, Tseng G, Rao U, Monga S . Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology. 2006; 44(4):1012-24. PMC: 1769554. DOI: 10.1002/hep.21328. View

18.

Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Quertermous T . Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest. 2003; 112(1):30-41. PMC: 162283. DOI: 10.1172/JCI17034. View

19.

Yang Z, Poon R . Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken). 2008; 291(6):721-34. DOI: 10.1002/ar.20668. View